Espoo, Finland, 8 February 2021 – Medtentia International Ltd Oy (“Medtentia”), the cardiovascular device company developing new transformative solutions for mitral valve repair based on its groundbreaking helix technology platform, today announced that it has reached major milestones in its research and development work. Medtentia’s transcatheter mitral...
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit...
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit...
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit...
Espoo, Finland, 6 December 2019 – Medtentia, the cardiovascular device company developing new transformative solutions for mitral valve repair, announces that data on its transcatheter mitral valve will be presented at the ICI Meeting in Tel Aviv, Israel, 8-10 December 2019. Clinical advisor to Medtentia, Kari Kervinen,...
Espoo, Finland, 25 September 2019 – Medtentia, the cardiovascular device company developing new transformative solutions for mitral valve repair, today announces that the Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA), has granted Breakthrough Device designation for its lead...
Medtentia, the cardiovascular device company developing new transformative solutions for mitral valve repair, today announces that it will present at Transcatheter Cardiovascular Therapeutics, taking place at the Colorado Convention Center in Denver, Colorado, 29 October – 2 November. Clinical Adviser, Professor Bruno Scheller MD, will present CathHELIX:...
Medtentia, the cardiovascular device company developing new transformative solutions for mitral valve repair, today announces that it will present data at the 2017 PCR Innovators Day, taking place at ExCel London on 24 September. Clinical Advisor, Professor Bruno Scheller MD, will give a presentation entitled Transcatheter CathHELIX...
Medtentia, the cardiovascular device company developing new transformative solutions for mitral valve repair, today announces that Medtentia Annuloplasty System initial study data will be presented as an e-poster at the Heart Valve Society Scientific Meeting 2017, taking place between 2-4 March at the Grimaldi Forum,...
The statistical analysis of Medtentia’s proof-of-concept study evaluating the Medtentia Annuloplasty Ring (MAR) has recently been completed. As previously expected based on preliminary data analyses, the main safety- and performance- related objectives of the study were successfully achieved. The newly analyzed results indicate that the MAR...